Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | Mechanisms of resistance to immunotherapy in NHL

Nilanjan Ghosh • 10 Jun 2022
EHA 2022
Lymphoma Non-Hodgkin Lymphoma

Nilanjan Ghosh, MD, PhD, Atrium Health Levine Cancer Institute, Charlotte, NC, briefly discusses mechanisms of resistance to immunotherapy in non-Hodgkin lymphoma (NHL), drawing focus on T-cell exhaustion, myeloid-derived suppressor cells, and antigen escape. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research funding, honoraria, consulting: BMS
Consulting: Lilly, Genentech/Roche

More from Nilanjan Ghosh

Key takeaways & trials from ICML in DLBCL, MCL, and FL: POLARGO, STARGLO, MorningSun & more 15:00
Key takeaways & trials from ICML in DLBCL, MCL, and FL: POLARGO, STARGLO, MorningSun & more
Nilanjan Ghosh • 27 Jun 2025
An overview of CAR T-cell therapies in the treatment of patients with MCL 6:46
An overview of CAR T-cell therapies in the treatment of patients with MCL
Nilanjan Ghosh • 26 Jun 2024
The effectiveness of ibrutinib flexible dosing regimens on TTNT in CLL/SLL 2:24
The effectiveness of ibrutinib flexible dosing regimens on TTNT in CLL/SLL
Nilanjan Ghosh • 26 Jun 2024
The real-world effectiveness of venetoclax-based therapy after BTKis in patients with CLL 3:50
The real-world effectiveness of venetoclax-based therapy after BTKis in patients with CLL
Nilanjan Ghosh • 26 Jun 2024

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals